Gastrointestinal adverse reactions with Levocarnitine Oral Solution or Levocarnitine Oral Solution (Sugar Free) dissolved in liquids might be avoided by a slow consumption of the solution or by a greater dilution
Although substantial challenges remain at both the mechanistic and translational levels, LDs are emerging as potential multi-organ targets, and further rigorous preclinical and clinical studies are required to substantiate their therapeutic value
Key points Obesity is a risk factor for developing osteoarthritis (OA), gout, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), and is associated with higher disease activity and/or severity, and worse response to common treatments
Wellberg is also speaking to her fellow scientists through the review article
dosage, titration schedule, and treatment duration must be determined based on a formal research protocol